Aimee C. Talleur
St. Jude Children's Research Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Aimee C. Talleur as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:06 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04881240 · Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ LeukemiaSt. Jude Children's Research Hospital · recruiting · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL · principal investigator
- Ph1/Ph2NCT03573700 · Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital · active not recruiting · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Improving CAR T-cell therapy for Pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL)K08CA279927 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · fiscal years 2024 to 2026 · $289,458 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 13:06 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed